A catalogue of treatment and technologies for malignant pleural mesothelioma

Expert Review of Anticancer Therapy

Volumn 16, Issue 4, 2016, Pages 455-463

  Schunselaar, Laurel M ^a   Quispel Janssen, Josine M M F ^a   Neefjes, Jacques J C ^a   Baas, Paul ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Chemotherapy; immunotherapy; mesothelioma; mouse models; pre clinical models; primary tumor culture; targeted agent; treatment

Indexed keywords

ALISERTIB; ALKYLATING AGENT; AMATUXIMAB; BEVACIZUMAB; BORTEZOMIB; CETUXIMAB; CISPLATIN; CIXUTUMUMAB; DASATINIB; DAUNORUBICIN; DEFACTINIB; DENDRITIC CELL VACCINE; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; DURVALUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EVEROLIMUS; GEFITINIB; IMATINIB; METHOTREXATE; NAVELBINE; NIVOLUMAB; PEMBROLIZUMAB; PEMETREXED; TAXANE DERIVATIVE; TICILIMUMAB; UNINDEXED DRUG; VASCULOTROPIN INHIBITOR; VORINOSTAT; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CELL ADHESION; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; HUMAN; IMMUNE RESPONSE; NEPHROTOXICITY; NONHUMAN; ONCOLYTIC VIROTHERAPY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLEURA MESOTHELIOMA; REVIEW; SURVIVAL TIME; TREATMENT DURATION; TREATMENT OUTCOME; ANIMAL; DISEASE MODEL; IMMUNOTHERAPY; LUNG NEOPLASMS; MESOTHELIOMA; MOLECULARLY TARGETED THERAPY; MOUSE; PATHOLOGY; PLEURAL NEOPLASMS; PROCEDURES; TUMOR CELL CULTURE;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; MESOTHELIOMA; MICE; MOLECULAR TARGETED THERAPY; ONCOLYTIC VIROTHERAPY; PLEURAL NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 84962294619     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.2016.1162100     Document Type: Review

References (88)

1. Martini N, McCormack PM, Bains MS, et al. Pleural mesothelioma. Ann Thorac Surg. 1987; 43 (1): 113-120
2. Suzuki Y. Pathology of human malignant mesothelioma-preliminary analysis of 1,517 mesothelioma cases. Ind Health. 2001; 39 (2): 183-185
3. Van Zandwijk N, Clarke C, Henderson D, et al. Guidelines for the diagnosis and treatment of malignant pleural mesothelioma. J Thorac Dis. 2013; 5 (6): E254-307
4. Buikhuisen WA, Hiddinga BI, Baas P, et al. Second line therapy in malignant pleural mesothelioma: A systematic review. Lung Cancer. 2015; 89 (3): 223-231
5. Henley SJ, Larson TC, Wu M, et al. Mesothelioma incidence in 50 states and the District of Columbia, United States, 2003-2008. Int J Occup Environ Health. 2013; 19 (1): 1-10
6. Baas P, Fennell D, Kerr KM, et al. Malignant pleural mesothelioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-updagger. Ann Oncol. 2015; 26: v31-v39
7. Scherpereel A, Astoul P, Baas P, et al. Guidelines of the European respiratory society and the European society of thoracic surgeons for the management of malignant pleural mesothelioma. Eur Respir J. 2010; 35 (3): 479-495
8. Remon J, Lianes P, Martínez S, et al. Malignant mesothelioma: new insights into a rare disease. Cancer Treat Rev. 2013; 39 (6): 584-591
9. Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med. 1960; 17 (p): 260-271
10. Christoph DC, Eberhardt WE. Systemic treatment of malignant pleural mesothelioma: new agents in clinical trials raise hope of relevant improvements. Curr Opin Oncol. 2014; 26 (2): 171-181
11. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003; 21 (14): 2636-2644
12. Van Meerbeeck JP, Gaafar R, Manegold C, et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European organisation for research and treatment of cancer lung cancer group and the National Cancer Institute of Canada. J Clin Oncol. 2005; 23 (28): 6881-6889
13. Szulkin A, Nilsonne G, Mundt F, et al. Variation in drug sensitivity of malignant mesothelioma cell lines with substantial effects of selenite and bortezomib, highlights need for individualized therapy. PLoS One. 2013; 8 (6): e65903
14. Szulkin A, Ötvös R, Hillerdal C-O, et al. Characterization and drug sensitivity profiling of primary malignant mesothelioma cells from pleural effusions. BMC Cancer. 2014; 14: 709
15. Janne PA. Chemotherapy for malignant pleural mesothelioma. Clin Lung Cancer. 2003; 5 (2): 98-106
16. Ryan CW, Herndon J, Vogelzang NJ. A review of chemotherapy trials for malignant mesothelioma. Chest. 1998; 113 (1 Suppl): 66S-73S
17. Tomek S, Emri S, Krejcy K, et al. Chemotherapy for malignant pleural mesothelioma: past results and recent developments. Br J Cancer. 2003; 88 (2): 167-174
18. Berghmans T, Paesmans M, Lalami Y, et al. Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-Analysis. Lung Cancer. 2002; 38 (2): 111-121
19. Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov. 2005; 4 (4): 307-320
20. Kelly RJ, Sharon E, Hassan R. Chemotherapy and targeted therapies for unresectable malignant mesothelioma. Lung Cancer. 2011; 73 (3): 256-263
21. Niyikiza C, Baker SD, Seitz DE, et al. Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther. 2002; 1 (7): 545-552
22. Manegold C, Symanowski J, Gatzemeier U, et al. Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann Oncol. 2005; 16 (6): 923-927
23. Astoul P, Roca E, Galateau-Salle F, et al. Malignant pleural mesothelioma: from the bench to the bedside. Respiration. 2012; 83 (6): 481-493
24. Buikhuisen WA, Burgers JA, Vincent AD, et al. Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study. Lancet Oncol. 2013; 14 (6): 543-551
25. Zalcman G, Mazieres J, Margery J, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the mesothelioma avastin cisplatin pemetrexed study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2015. [Epub ahead of print]
26. Fennell DA, McDowell C, Busacca S, et al. Phase II clinical trial of first or second-line treatment with bortezomib in patients with malignant pleural mesothelioma. J Thorac Oncol. 2012; 7 (9): 1466-1470
27. OBrien MER, Gaafar RM, Popat S, et al. Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European organisation for research and treatment of cancer 08052). Eur J Cancer. 2013; 49 (13): 2815-2822
28. Krug LM, Kindler HL, Calvert H, et al. Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Oncol. 2015; 16 (4): 447-456
29. Ou S-HI, Moon J, Garland LL, et al. SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM). J Thorac Oncol. 2015; 10 (2): 387-391
30. Devine A. Defactinib Disappoints. Can Other Trials Pick Up the Slack? 2015 Oct 8. Available from: www.mesotheliomaguide.com
31. Gregorc V, Zucali PA, Santoro A, et al. Phase II study of asparagine-glycine-Arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma. J Clin Oncol. 2010; 28 (15): 2604-2611
32. Gaafar RM, Favaretto AG, Gregorc V, et al. Phase III trial (NGR015) with NGR-hTNF plus best investigator choice (BIC) versus placebo plus BIC in previously treated patients with advanced malignant pleural mesothelioma (MPM). ASCO Annual Meeting. 2015; 33 (suppl; abstr 7501)
33. Hassan R, Kindler HL, Jahan T, et al. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res. 2014; 20 (23): 5927-5936
34. Hassan R, Bera T, Pastan I. Mesothelin: a new target for immunotherapy. Clin Cancer Res. 2004; 10 (12 Pt 1): 3937-3942
35. Chowdhury PS, Chang K, Pastan I. Isolation of anti-mesothelin antibodies from a phage display library. Mol Immunol. 1997; 34 (1): 9-20
36. Hassan R, et al. Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-Associated mesothelin. Cancer Immun. 2007; 7: 20
37. Takagi-Kimura M, Yamano T, Tamamoto A, et al. Enhanced antitumor efficacy of fiber-modified, midkine promoter-regulated oncolytic adenovirus in human malignant mesothelioma. Cancer Sci. 2013; 104 (11): 1433-1439
38. Willmon C, Diaz RM, Wongthida P, et al. Vesicular stomatitis virus-induced immune suppressor cells generate antagonism between intratumoral oncolytic virus and cyclophosphamide. Mol Ther. 2011; 19 (1): 140-149
39. Willmon CL, Saloura V, Fridlender ZG, et al. Expression of IFN-beta enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma. Cancer Res. 2009; 69 (19): 7713-7720
40. Kawasaki Y, Tamamoto A, Takagi-Kimura M, et al. Replication-competent retrovirus vector-mediated prodrug activator gene therapy in experimental models of human malignant mesothelioma. Cancer Gene Ther. 2011; 18 (8): 571-578
41. Li H, Peng K-W, Dingli D, et al. Oncolytic measles viruses encoding interferon beta and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy. Cancer Gene Ther. 2010; 17 (8): 550-558
42. Silberhumer GR, Brader P, Wong J, et al. Genetically engineered oncolytic Newcastle disease virus effectively induces sustained remission of malignant pleural mesothelioma. Mol Cancer Ther. 2010; 9 (10): 2761-2769
43. Gauvrit A, et al. Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response. Cancer Res. 2008; 68 (12): 4882-4892
44. Zhu ZB, Makhija SK, Lu B, et al. Targeting mesothelioma using an infectivity enhanced survivin-conditionally replicative adenoviruses. J Thorac Oncol. 2006; 1 (7): 701-711
45. Robinson BW, Robinson C, Lake RA. Localised spontaneous regression in mesothelioma-possible immunological mechanism. Lung Cancer. 2001; 32 (2): 197-201
46. Anraku M, Cunningham KS, Yun Z, et al. Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2008; 135 (4): 823-829
47. Leigh RA, Webster I. Lymphocytic infiltration of pleural mesothelioma and its significance for survival. S Afr Med J. 1982; 61 (26): 1007-1009
48. Cedrés S, Ponce-Aix S, Zugazagoitia J, et al. Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). PLoS One. 2015; 10 (3): e0121071
49. Mansfield AS, Roden AC, Peikert T, et al. B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis. J Thorac Oncol. 2014; 9 (7): 1036-1040
50. Hassan R, Miller AC, Sharon E, et al. Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression. Sci Transl Med. 2013; 5 (208): 208ra147
51. Brahmer JR, Tykodi SS, Chow LQM, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012; 366 (26): 2455-2465
52. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015; 373 (17): 1627-1639
53. Rizvi NA, Mazières J, Planchard D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-Arm trial. Lancet Oncol. 2015; 16 (3): 257-265
54. Weber JS, DAngelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015; 16 (4): 375-384
55. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015; 372 (4): 320-330
56. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011; 364 (26): 2517-2526
57. Hodi FS, ODay SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363 (8): 711-723
58. Calles A, Liao X, Sholl LM, et al. Expression of PD-1 and its ligands, PD-L1 and PD-L2, in smokers and never smokers with KRAS mutant lung cancer. J Thorac Oncol. 2015; 10: 1726-1735
59. Llosa NJ, Cruise M, Tam A, et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 2015; 5 (1): 43-51
60. Lyford-Pike S, Peng S, Young GD, et al. Evidence for a role of the PD-1: PD-L1pathway in immune resistance of HPV-Associated head and neck squamous cell carcinoma. Cancer Res. 2013; 73 (6): 1733-1741
61. Tarhini AA, Zahoor H, Yearley JH, et al. Tumor associated PD-L1 expression pattern in microscopically tumor positive sentinel lymph nodes in patients with melanoma. J Transl Med. 2015; 13 (1): 319
62. Alley E, Molife LR, Santoro A, et al. Clinical safety and efficacy of pembrolizumab (MK-3475) in patients with malignant pleural mesothelioma: preliminary results from KEYNOTE-001. AACR annual meeting; Philadelphia; 2015 Apr 19. abstract # CT103
63. Calabrò L, Morra A, Fonsatti E, et al. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-Arm, phase 2 trial. Lancet Oncol. 2013; 14 (11): 1104-1111
64. Calabrò L, Morra A, Fonsatti E, et al. Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-Arm, phase 2 study. Lancet Respir Med. 2015; 3 (4): 301-309
65. Hegmans JPJJ, Hemmes A, Aerts JG, et al. Immunotherapy of murine malignant mesothelioma using tumor lysate-pulsed dendritic cells. Am J Respir Crit Care Med. 2005; 171 (10): 1168-1177
66. Hegmans JP, Veltman JD, Lambers ME, et al. Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma. Am J Respir Crit Care Med. 2010; 181 (12): 1383-1390
67. Krug LM, Dao T, Brown AB, et al. WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer. Cancer Immunol Immunother. 2010; 59 (10): 1467-1479
68. Hudson AL, Weir C, Moon E, et al. Establishing a panel of chemo-resistant mesothelioma models for investigating chemo-resistance and identifying new treatments for mesothelioma. Sci Rep. 2014; 4: 6152
69. Kamb A. Whats wrong with our cancer models? Nat Rev Drug Discov. 2005; 4 (2): 161-165
70. Kim JB. Three-dimensional tissue culture models in cancer biology. Semin Cancer Biol. 2005; 15 (5): 365-377
71. Kalra N, et al. Mesothelioma patient derived tumor xenografts with defined BAP1 mutations that mimic the molecular characteristics of human malignant mesothelioma. BMC Cancer. 2015; 15: 376
72. Barbone D, Cheung P, Battula S, et al. Vorinostat eliminates multicellular resistance of mesothelioma 3D spheroids via restoration of Noxa expression. PLoS One. 2012; 7 (12): e52753
73. Barbone D, et al. The Bcl-2 repertoire of mesothelioma spheroids underlies acquired apoptotic multicellular resistance. Cell Death Dis. 2011; 2: e174
74. Ruppen J, Cortes-Dericks L, Marconi E, et al. A microfluidic platform for chemoresistive testing of multicellular pleural cancer spheroids. Lab Chip. 2014; 14 (6): 1198-1205
75. Gordon GJ, Mani M, Maulik G, et al. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma. Cancer Chemother Pharmacol. 2008; 61 (4): 549-558
76. Sartore-Bianchi A, Gasparri F, Galvani A, et al. Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma. Clin Cancer Res. 2007; 13 (19): 5942-5951
77. Wang Y, Rishi AK, Puliyappadamba VT, et al. Targeted proteasome inhibition by velcade induces apoptosis in human mesothelioma and breast cancer cell lines. Cancer Chemother Pharmacol. 2010; 66 (3): 455-466
78. Patterson MJ, Sutton RE, Forrest I, et al. Assessing the function of homologous recombination DNA repair in malignant pleural effusion (MPE) samples. Br J Cancer. 2014; 111 (1): 94-100
79. Xiang X, Phung Y, Feng M, et al. The development and characterization of a human mesothelioma in vitro 3D model to investigate immunotoxin therapy. PLoS One. 2011; 6 (1): e14640
80. Kim K-U, Wilson SM, Abayasiriwardana KS, et al. A novel in vitro model of human mesothelioma for studying tumor biology and apoptotic resistance. Am J Respir Cell Mol Biol. 2005; 33 (6): 541-548
81. Wilson SM, Barbone D, Yang T-M, et al. mTOR mediates survival signals in malignant mesothelioma grown as tumor fragment spheroids. Am J Respir Cell Mol Biol. 2008; 39 (5): 576-583
82. Jongsma J, Van Montfort E, Vooijs M, et al. A conditional mouse model for malignant mesothelioma. Cancer Cell. 2008; 13 (3): 261-271
83. Kane AB. Animal models of malignant mesothelioma. Inhal Toxicol. 2006; 18 (12): 1001-1004
84. Stathopoulos GT, Kalomenidis I. Animal models of malignant pleural effusion. Curr Opin Pulm Med. 2009; 15 (4): 343-352
85. Lo Iacono M, Monica V, Righi L, et al. Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study. J Thorac Oncol. 2015; 10 (3): 492-499
86. Guo G, Chmielecki J, Goparaju C, et al. Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma. Cancer Res. 2015; 75 (2): 264-269
87. De Rienzo A, Archer MA, Yeap BY, et al. Gender-specific molecular and clinical features underlie malignant pleural mesothelioma. Cancer Res. 2015;76(2):319-328
88. LaFave LM, Béguelin W, Koche R, et al. Loss of BAP1 function leads to EZH2-dependent transformation. Nat Med. 2015; 21 (11): 1344-1349.